Partial agonists in schizophrenia

D. A. Cousins and A. H. Young

School of Neurology, Neurobiology and Psychiatry (Psychiatry), University of Newcastle upon Tyne, Leazes Wing, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.

Correspondence: E-mail: d.a.cousins{at}ncl.ac.uk

EDITED BY KHALIDA ISMAIL

The editorial by Bolonna & Kerwin (2005) is both timely and important. The authors succinctly present the case for the use of partial agonists of dopamine receptors, concluding that ‘the reviewed evidence suggests a promising future for dopamine receptor partial agonists’. While this is arguably true on the basis of the evidence presented, theoretical and empirical concerns regarding the use of these medications remain.

The introduction of aripiprazole on an individual patient level may prove problematic (DeQuardo, 2004; Ramaswamy et al, 2004). Although effective switching strategies from atypical agents to aripiprazole have been described, a number of reports of worsening psychosis following the introduction of aripiprazole (DeQuardo, 2004; Ramaswamy et al, 2004) have been published. While these cases may be accounted for by unrelated illness relapse, other theoretical explanations should be considered. Up-regulation of dopamine receptors is well recognised during treatment with neuroleptics, and results in supersensitivity to dopamine at the sites of receptor blockage. This has led to the concept of a neuroleptic-induced supersensitivity psychosis (Steiner et al, 1990) wherein up-regulation effectively outstrips receptor blockade with emergent psychosis resistant to treatment. Supersensitivity could explain cases of psychosis developing with aripiprazole. Cessation of an antagonist with subsequent introduction of a partial agonist could result in a net excess of neurotransmission due to over-stimulation of a supersensitive system (despite the partial agonist demonstrating sub-maximal stimulation in normal systems). The high receptor affinity of partial agonists may make such symptoms difficult to treat, as few drugs are likely to be able to displace these agents from receptor complexes. Drugs that can displace partial agonists run the risk of negating the therapeutic effects of stabilisation of the dopaminergic system in schizophrenia, perhaps most importantly at times of relapse when patients are likely to receive ‘as required’ doses of potent D2 antagonists.

While empirical evidence largely supports the primary efficacy of these agents (DeLeon et al, 2004), clinical experience of partial agonists is in its infancy. Goodquality data from naturalistic studies are required to establish the effectiveness of these drugs, but in the meantime we call for post-marketing surveillance to quantify the scale of the problem of cross-titration.

REFERENCES

Bolonna, A. A. & Kerwin, R. W. (2005) Partial agonism and schizophrenia. British Journal of Psychiatry, 186, 7 –10[Free Full Text]

DeLeon, A., Patel, N. C. & Crismon, M. L. (2004) Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics, 26, 649 –666.[CrossRef][Medline]

DeQuardo, J. R. (2004) Worsened agitation with aripiprazole: adverse effect of partial agonism? Journal of Clinical Psychiatry, 65, 132 –133.

Ramaswamy, S., Vijay, D., William, M., et al (2004) Aripiprazole possibly worsens psychosis. International Clinical Psychopharmacology, 19, 45 –48.[CrossRef][Medline]

Steiner, W., Laporta, M. & Chouinard, G. (1990) Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatrica Scandinavica, 81, 437 –440.[Medline]




eLetters:

Read all eLetters

The 'dirtier' the better
Adrian Blaj, et al.
BJP Online, 27 Apr 2005 [Full text]

This Article
Full Text (PDF)
Submit a response
View responses
Alert me when this article is cited
Alert me when eLetters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Cousins, D. A.
Articles by Young, A. H.
Articles citing this Article
PubMed
PubMed Citation
Articles by Cousins, D. A.
Articles by Young, A. H.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals